UroToday - Equivalent and Sufficient Effects of Leuprolide Acetate and Goserelin Acetate to Suppress Serum Testosterone Levels in Patients With Prostate Cancer - Abstract

[Guest guest]

http://www.urotoday.com/browse_categories/prostate_cancer/equivalent_and_suf

ficient_effects_of_leuprolide_acetate_and_goserelin_acetate_to_suppress_seru

m_testosterone_levels_in_patients_with_prostate_cancer__abstract.html

Wednesday, 13 February 2008

Department of Urology, Cancer Institute Hospital, Japanese Foundation of

Cancer Research, Tokyo, Japan.

To compare the effects of leuprolide acetate and goserelin acetate for

suppressing serum testosterone levels in Japanese patients with prostate

cancer, as several recent studies suggested that serum testosterone is not

always suppressed below the upper limit of the castration range in patients

using luteinizing hormone-releasing hormone (LH-RH) agonists, especially

leuprolide acetate.

In all, 232 patients with prostate cancer, whose serum testosterone levels

were measured before and during treatment using a 1- or 3-monthly

formulation of leuprolide or goserelin, were enrolled in a retrospective

study. The mean age of the patients was 69.8 years and the mean testosterone

level before the LHRH treatment was 4.54 ng/mL. The patients had their

testosterone levels assessed a mean (range) of 5.4 (1-35) times during the

LHRH treatment. A castrate serum testosterone level was defined as < /=0.5

ng/mL.

The mean maximum testosterone level during 1-monthly leuprolide (40

patients), 3-monthly leuprolide (68), 1-monthly goserelin (50), or 3-monthly

goserelin (74) treatment was 0.22, 0.20, 0.19 and 0.20 ng/mL, respectively

(not significant). Four patients, including two treated with 1-monthly

leuprolide, one with 3-monthly leuprolide and one with 3-monthly goserelin,

had serum testosterone above the castrate level, with a maximum of 0.5-0.65

ng/mL. Three of these patients had elevated testosterone only once or twice

during the follow-up, and the remaining patient had serum testosterone

fluctuating at 0.4-0.6 ng/mL throughout the follow-up.

One- and 3-monthly formulations of leuprolide and goserelin have equivalent

and sufficient effects to suppress serum testosterone levels in men with

prostate cancer. There were testosterone levels just outside the castrate

range in a few patients during treatment.

Written by

Fujii Y, Yonese J, Kawakami S, Yamamoto S, Okubo Y, Fukui I.

Reference

BJU Int. 2008 Jan 8. Epub ahead of print.

PubMed Abstract

PMID:18190637